320 related articles for article (PubMed ID: 32053990)
1. Beyond PSA: The Role of Prostate Health Index (phi).
Ferro M; De Cobelli O; Lucarelli G; Porreca A; Busetto GM; Cantiello F; Damiano R; Autorino R; Musi G; Vartolomei MD; Muto M; Terracciano D
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32053990
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen and other serum and urine markers in prostate cancer.
Stephan C; Ralla B; Jung K
Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
[TBL] [Abstract][Full Text] [Related]
3. The role of prostate cancer biomarkers in undiagnosed men.
Dani H; Loeb S
Curr Opin Urol; 2017 May; 27(3):210-216. PubMed ID: 28212119
[TBL] [Abstract][Full Text] [Related]
4. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
5. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G
Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961
[TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
Grönberg H; Eklund M; Picker W; Aly M; Jäderling F; Adolfsson J; Landquist M; Haug ES; Ström P; Carlsson S; Nordström T
Eur Urol; 2018 Dec; 74(6):722-728. PubMed ID: 30001824
[TBL] [Abstract][Full Text] [Related]
7. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range.
Ito K; Miyakubo M; Sekine Y; Koike H; Matsui H; Shibata Y; Suzuki K
World J Urol; 2013 Apr; 31(2):305-11. PubMed ID: 22903772
[TBL] [Abstract][Full Text] [Related]
9. Value of a Statistical Model Based on Four Kallikrein Markers in Blood, Commercially Available as 4Kscore, in All Reasonable Prostate Biopsy Subgroups.
Vickers AJ; Vertosick EA; Sjoberg DD
Eur Urol; 2018 Oct; 74(4):535-536. PubMed ID: 29903434
[No Abstract] [Full Text] [Related]
10. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
Filella X; Foj L
Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
[TBL] [Abstract][Full Text] [Related]
11. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
Parekh DJ; Punnen S; Sjoberg DD; Asroff SW; Bailen JL; Cochran JS; Concepcion R; David RD; Deck KB; Dumbadze I; Gambla M; Grable MS; Henderson RJ; Karsh L; Krisch EB; Langford TD; Lin DW; McGee SM; Munoz JJ; Pieczonka CM; Rieger-Christ K; Saltzstein DR; Scott JW; Shore ND; Sieber PR; Waldmann TM; Wolk FN; Zappala SM
Eur Urol; 2015 Sep; 68(3):464-70. PubMed ID: 25454615
[TBL] [Abstract][Full Text] [Related]
12. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
[No Abstract] [Full Text] [Related]
14. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
Ferro M; Bruzzese D; Perdonà S; Marino A; Mazzarella C; Perruolo G; D'Esposito V; Cosimato V; Buonerba C; Di Lorenzo G; Musi G; De Cobelli O; Chun FK; Terracciano D
PLoS One; 2013; 8(7):e67687. PubMed ID: 23861782
[TBL] [Abstract][Full Text] [Related]
15. Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that the PHI consistently outperforms PSA across diverse populations.
Loeb S
BJU Int; 2015 Apr; 115(4):500. PubMed ID: 25808708
[No Abstract] [Full Text] [Related]
16. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
17. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
[TBL] [Abstract][Full Text] [Related]
18. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
19. Use of the Prostate Health Index and Density in 3 Outpatient Centers to Avoid Unnecessary Prostate Biopsies.
Schulze A; Christoph F; Sachs M; Schroeder J; Stephan C; Schostak M; Koenig F
Urol Int; 2020; 104(3-4):181-186. PubMed ID: 32224611
[TBL] [Abstract][Full Text] [Related]
20. A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer.
Song J; Ma S; Sokoll LJ; Eguez RV; Höti N; Zhang H; Mohr P; Dua R; Patil D; May KD; Williams S; Arnold R; Sanda MG; Chan DW; Zhang Z
Theranostics; 2021; 11(13):6214-6224. PubMed ID: 33995654
[No Abstract] [Full Text] [Related]
[Next] [New Search]
